Search Within

Christopher Jon Forlenza

Formats
  1. Journal Article (23)
  2. Meeting Abstract (22)
  3. Review (3)
  4. Research Letter (1)
Groups
  1. Hematologic Malignancies Service (49)
  2. Pediatrics, Department of (49)
  3. Center for Hematologic Malignancies (26)
  4. Pediatric Leukemia (20)
  5. Department of Medicine (15)
  6. Epidemiology and Biostatistics (14)

More Groups

People
  1. Neerav Shukla (18)
  2. Peter Steinherz (14)
  3. Kavitha Ramaswamy (10)
  4. Audrey Mauguen (9)
  5. Nancy Kernan (8)
  6. Kevin Curran (7)

More People

Years
  1. 2025 (4)
  2. 2024 (3)
  3. 2023 (9)
  4. 2022 (6)
  5. 2021 (4)
  6. 2020 (4)

More Years

Publications
  1. Blood (12)
  2. Pediatric Blood and Cancer (7)
  3. Blood Advances (4)
  4. Biology of Blood and Marrow Transplantation (3)
  5. International Journal of Radiation Oncology, Biology, Physics (2)
  6. Journal of Clinical Oncology (2)

More Publications

Publishers
  1. American Society of Hematology (16)
  2. Elsevier Inc. (9)
  3. Wiley Periodicals, Inc (7)
  4. American Association for Cancer Research (2)
  5. American Society of Clinical Oncology (2)
  6. Lippincott Williams & Wilkins (2)

More Publishers

Results (49)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Inotuzumab ozogamicin is an effective salvage therapy in relapsed/refractory B-cell acute lymphoblastic leukemia with high-risk molecular features, including TP53 loss
    Meeting Abstract

    Yang, X.; King, A. C.; Kabel, C. C.; Forlenza, C. J.; Park, J. H.; Geyer, M. B.
    Blood (2019)

    Fulltext@MSK | Save
  • Blinatumomab as a successful bridge to hematopoietic stem cell transplant in a down syndrome patient with relapsed B-precursor acute lymphoblastic leukemia
    Meeting Abstract

    Smith, M. H.; Steinherz, P. G.; Shukla, N.; Forlenza, C. J.; Prockop, S. E.; Ramaswamy, K.
    Biology of Blood and Marrow Transplantation (2019)

    Fulltext@MSK | Save
  • Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL
    Journal Article

    Curran, K. J.; Margossian, S. P.; Kernan, N. A.; Silverman, L. B.; Williams, D. A.; Shukla, N.; Kobos, R.; Forlenza, C. J.; Steinherz, P.; Prockop, S.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Using genomic data for selecting the treatment of lymphoma patients
    Review

    Batlevi, C. L.; Shah, G.; Forlenza, C.; Intlekofer, A.
    Current Opinion in Hematology (2019)

    Fulltext@MSK | Save
  • Maintenance chemotherapy to reduce the risk of a metachronous Wilms tumor in children with bilateral nephroblastomatosis
    Journal Article

    Ortiz, M. V.; Fernandez-Ledon, S.; Ramaswamy, K.; Forlenza, C. J.; Shukla, N. N.; Kobos, R.; Heaton, T. E.; LaQuaglia, M. P.; Steinherz, P. G.
    Pediatric Blood and Cancer (2019)

    Fulltext@MSK | Save
  • Clofarabine with topotecan, vinorelbine, and thiotepa (TVTC) in children and young adults with relapsed or refractory acute myeloid leukemia
    Meeting Abstract

    Ramaswamy, K.; Forlenza, C.; Kobos, R.; Steinherz, P. G.; Shukla, N.
    Blood (2018)

    Fulltext@MSK | Save
  • A case of KMT2A-SEPT9 fusion-associated acute megakaryoblastic leukemia
    Journal Article

    Forlenza, C. J.; Zhang, Y.; Yao, J.; Benayed, R.; Steinherz, P.; Ramaswamy, K.; Kessel, R.; Roshal, M.; Shukla, N.
    Cold Spring Harbor Molecular Case Studies (2018)

    Fulltext@MSK | Save
  • Unicentric Castleman disease in the mediastinum
    Journal Article

    Wala, S. J.; Fallon, E. M.; Forlenza, C. J.; Shukla, N.; LaQuaglia, M. P.
    Journal of Pediatric Surgery Case Reports (2018)

    Fulltext@MSK | Save
  • Brentuximab vedotin plus bendamustine is an effective salvage regimen for pediatric patients with relapsed Hodgkin lymphoma
    Meeting Abstract

    Gulati, N.; Boulad, F.; Cancio, M. I.; Curran, K. J.; Jackson, C.; Kernan, N.; Kung, A. L.; O'Reilly, R.; Prockop, S.; Ramaswamy, K.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • High dose cyclophosphamide and pre-treatment disease burden dictate response and survival in a multicenter clinical trial using CD19-specific CAR T cells for relapsed/refractory B-ALL
    Meeting Abstract

    Curran, K. J.; Margossian, S. P.; Kernan, N. A.; Silverman, L. B.; Park, J. H.; Sauter, C. S.; Smith, E. L.; Boulad, F.; Cancio, M. I.; Forlenza, C.; more...
    Blood (2017)

    Fulltext@MSK | Save